Welcome to the investor section of the site. The pages in this section of the website contain all information that is required to be disclosed in accordance with Rule 26 of the AIM Rules. The information can be accessed from the drop down menu of the Investors section.
To keep up to date with the latest news and events as they occur, we encourage investors to subscribe to our email news alert service.
Futura Medical plc is committed to enhancing shareholder value through the development of innovative, over the counter products for the consumer healthcare market, focused on sexual healthcare and pain relief management.
The following agreements have been signed for our products:
CSD500 - a condom clinically proven to help healthy men maintain a firmer and bigger erection during intercourse whilst wearing a condom. Agreement signed in April 2013 with Church and Dwight Co Inc for the distribution rights to CSD500 in North America and in a number of key European territories.
TPR100 - a topical treatment for the provision of pain relief using our DermaSys® technology. Agreement with GlaxoSmithKline plc (GSK) for the development and potential commercialisation of TPR100. GSK will fully fund and be responsible for all clinical activities leading to regulatory approvals. Assuming satisfactory clinical outcomes and regulatory approvals both parties expect to enter into a commercial distribution agreement in due course.
PET500 - an over the counter topical product for men with premature ejaculation. In 2011, we signed an exclusive worldwide agreement with Ansell Ltd for the distribution rights of PET500. Ansell is responsible for the product's manufacture, distribution and marketing and for funding of all regulatory work. We will be working closely with Ansell on the successful completion of any clinical work in territories where regulators require additional data. Ansell has developed the brand positioning and packaging for PET500 for initial sale in the USA where it will be marketed as part of Ansell's Lifestyles® brand. PET500 is progressing through its phased launch and roll out in the USA.
Our other drug products, which are not currently partnered, are:
MED2002 - a topical treatment for erectile dysfunction ("ED").
TPR100 Formulations - a higher strength TPR100 for more profound pain as well as other pain relief gels using alternative actives.
CRF100 - a topically applied cream to reduce cellulite.
In addition, we are evaluating the use of our proprietary delivery system DermaSys® with a range of other compounds.
Page last up-dated: 2 April 2013
Page last reviewed: 2 April 2013